Abstract
Background This is the first attempt to assess changes in liver abnormalities before and after contingency management (CM) to reduce heavy drinking beyond 30-days of follow-up.
Objective The main objective was to determine whether liver fibrosis and steatosis, measured using FibroScan, change significantly between baseline, 30-days, and 90-days among older adults who drink heavily at baseline, enrolled in the CM intervention for alcohol reduction. The secondary aim of the study was to assess whether the changes in liver outcome measures differ across alcohol consumption categories.
Methods A prospective study (ClinicalTrials.gov registry: NCT03353701) of 46 older adults (63% male, 76.1% Black, mean age = 56.4) with heavy drinking at the baseline, living with or without HIV infection was evaluated. A linear mixed-effects model was used to analyze the FibroScan Transient Elastography (TE for fibrosis) and Controlled Attenuation Parameter (CAP for steatosis).
Results There were no significant changes in liver fibrosis and steatosis measures after 90-days of drinking abstinence among heavy drinkers with or without stratified TE or CAP values at baseline.
Conclusions CM for drinking reduction may not be effective at least short-term prospective in preventing liver fibrosis and steatosis progression for subjects without severe liver disease at baseline.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov registry: NCT03353701
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT03353701
Funding Statement
This research was supported by Award Number [NIH U01AA020797] and [NIH T32AA025877 to S.A.] from the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health and [NIH T32DA017629 to V.R.] from the National Institute on Drug Abuse of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board at University of Miami (Study Number: 20170396).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- CM
- contingency management;
- TE
- Transient elastography;
- CAP
- Controlled attenuation parameter;
- HIV
- Human immunodeficiency virus;
- PLWH
- Persons living with HIV;
- NAFLD
- Non-alcoholic fatty liver disease;
- ALT
- aminotransferase;
- GGT
- gamma-glutamyl transferase;
- ALD
- Alcoholic-related liver disease;
- FIB-4
- Fibrosis-4;
- AST
- Aspartate aminotransferase;
- TLFB
- Alcohol timeline followback;
- HCV
- Hepatitis C
